Compare PURR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PURR | ABCL |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2025 | 2020 |
| Metric | PURR | ABCL |
|---|---|---|
| Price | $6.68 | $11.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.15 | ★ $8.40 |
| AVG Volume (30 Days) | 7.4M | ★ 7.8M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $148.78 | $21.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $3.01 | $2.75 |
| 52 Week High | $11.73 | $11.07 |
| Indicator | PURR | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 83.57 |
| Support Level | $5.75 | $3.38 |
| Resistance Level | $6.87 | N/A |
| Average True Range (ATR) | 0.33 | 0.74 |
| MACD | 0.09 | 0.62 |
| Stochastic Oscillator | 67.83 | 98.39 |
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. HSI aims to provide capital-efficient and productive access to the HYPE token for U.S. and institutional investors, generating compounding shareholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement. HSI is positioned to become the largest HYPE-focused digital asset treasury vehicle capitalizing on Hyperliquid's rapid growth and providing exposure to one of the largest and fastest growing revenue pools in digital assets.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.